On September 8, 2020, Chen Kui, Deputy Director of Zhejiang Provincial Drug Administration, visited Zhejiang Benefit Pharmaceutical for research and guidance, accompanied by Li Heda, Deputy Director of Lishui Municipal Market Supervision Bureau, Lan Yuecha, Director of Drug Production Supervision Department, and Liu Yao from Drug Production Supervision Department. Wu Lihua, Chairman of the company, and senior management of the pharmaceutical company warmly received them.

Zhang Liyun, Administrative Director, gave a detailed introduction to the production links and R&D of Chinese herbal pieces and traditional Chinese medicine formula granules through a remote real-time video system, and briefly reported on the company's overview, corporate culture, and Benefit's five-year development strategic layout plan.

At the forum, Chairman Wu Lihua made a detailed report on the current production status, product quality control, and market layout of Benefit's traditional Chinese medicine formula granules.

Subsequently, the two parties conducted extensive exchanges and communications on the relevant elements of quality standard control for traditional Chinese medicine formula granules and the future market of traditional Chinese medicine formula granules.

Finally, Deputy Director Chen Kui requested that Benefit should take advantage of the product advantages of traditional Chinese medicine formula granules, give full play to the resources of genuine medicinal materials in Lishui, and carry out in-depth research on "classic famous prescriptions". At the same time, he put forward many valuable suggestions and requirements for Benefit's future development.